Wednesday, August 17, 2016 10:58:46 AM
*** Issuance of KIT-302's clinical trial full study report
*** Completion of six-month stability testing of KIT-302
*** Submission to the FDA of the New Drug Application for KIT-302
*** Initiation of a renal function clinical trial to demonstrate the
*** Beneficial effects of KIT-302 on kidney function
ADS equivalents:
Ordinary shares - 6,769,860
Series "A" warrants - 6,835,669
Series 6/14 options - 4,572.75
Series 7/14 options - 2,307.6
Series 5/15 options - 2,239.3
Series 9/15 options - 86,000
Underwriter warrants - 157,945
Emp. Incentive options - 364,068
Pre-funded warrants - 865,000 (not tradable)
Agent warrants - 141,176
Fully diluted = 15,228,838 assuming everything is exercised
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM
ECGI Holdings Accelerates Strategic Initiatives by Securing First of Two $125,000 Convertible Notes • ECGI • Jun 4, 2024 12:15 PM